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Human congenital disorders impose a large impact not only on the affected individuals 
and their immediate families but also on communities, often inflicting great healthcare 
burdens. This thesis concentrates on one congenital disorder, Opitz Syndrome, which is 
a genetic disorder caused by mutations in MIDI. Opitz Syndrome (OS) patients present 
an array of clinical features including some of the more commonly found congenital 
structural anomalies, such as cleft lip and palate and hypospadias. The information 
gained from an enhanced understanding of the important cellular and molecular 
processes and pathways involved in Opitz Syndrome will subsequently aid in the 
elucidation of the basis of the individual clinical features. Only through an increased 
understanding of the underlying mechanisms of these congenital malformations can 
advances be made in prevention, diagnosis and ultimately treatment of them. 
